Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.

doi:10.1016/j.leukres.2015.10.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.

Leukemia research - 1 Dec 2015

Butrym Aleksandra, Rybka Justyna, Łacina Piotr, Gębura Katarzyna, Frontkiewicz Diana, Bogunia-Kubik Katarzyna, Mazur Grzegorz

Abstract excerpt

Recent studies have suggested that cereblon (CRBN) is essential for the anti-myeloma (MM) activity of immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide, and that dysregulation of Wnt/β-catenin pathway may be one of possible reasons of lenalidomide resistance. This prompted us to analyze the effect of polymorphisms within the genes coding for cereblon (CRBN (rs121918368 C>T)) and β-catenin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Immunologic Factors

Share to Lenalidomide

Share to Multiple Myeloma

Share to Neutropenia

Share to Peptide Hydrolases

Share to Thalidomide

Source

Open in PubMed

Identifiers

PMID: 26521987
DOI: 10.1016/j.leukres.2015.10.007

Genes

CTNNB1
CRBN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.PMID 26521987Read ↗

Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.Semantic proximity Read ↗

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.Semantic proximity Read ↗

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.Semantic proximity Read ↗

NCOA1 is a novel susceptibility gene for multiple myeloma in the Chinese population: A case-control study.Semantic proximity Read ↗

Cereblon enhancer methylation and IMiD resistance in multiple myelomaSemantic proximity Read ↗

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.Semantic proximity Read ↗

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapySemantic proximity Read ↗

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.Semantic proximity Read ↗

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideSemantic proximity Read ↗

Cereblon expression in multiple myeloma: not ready for prime timeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.